These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Author: Sugimoto T, Gotoh T, Yagyu S, Kuroda H, Iehara T, Hosoi H, Ohta S, Ohira M, Nakagawara A.
    Journal: Cancer Lett; 2013 Apr 30; 331(1):115-21. PubMed ID: 23268333.
    Abstract:
    Although more than 110 neuroblastoma (NB) cell lines have been established, there have been neither reports on the rate of success to establish NB cell lines, nor well-documented NB cell lines from long-term-survivors. We attempted to establish NB cell lines from 114 patients. Sixteen NB cell lines were established from 12 patients. The success rates to establish cell lines were 1.4% (1/70) from patients in early stages, 25.0% (11/44) from those in advanced stages, and 10.5% (12/114) from those in all stages respectively. Eleven of these 12 patients eventually died. The surviving patient, who was in stage 4 with MYCN-amplification, has been event-free for 19 years after completing therapy. The serum MYCN DNA level in patient TK was very high before therapy, decreased after chemotherapy, and has remained at the normal levels until now. The gene expression profiling of the primary tumor and the K-N-TK cell line was analyzed with an NB-specific cDNA microarray, and indicated that the probability of 5-year survival was extremely low. Microarray-based comparative genomic hybridization (CGH) analysis indicated that genomic aberration profiles of the cell line were uncommon, with MYCN amplification, 17q gain and 11q loss. A unique KP-N-TK cell line, established from an event-free survivor, will be a useful tool for investigating how a patient can survive a tumor with an extremely poor prognosis.
    [Abstract] [Full Text] [Related] [New Search]